Friess Associates’s Quest Diagnostics DGX Stock Holding History

Friess Associates’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-49,200	Closed	-$3.95M	–	108
2020 Q1	$3.95M	Buy	+49,200	New	+$5.09M	0.39%	70

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Friess Associates's DGX Position: Q2 2020 in Review

Friess Associates sold out of Quest Diagnostics (DGX) in Q2 2020, closing a stake of 49,200 shares — an estimated $3.95M sold.

Friess Associates first reported a position in DGX in Q1 2020 and held it in 1 quarter. The position peaked at $3.95M in Q1 2020. 748 funds tracked by Wall St. Rank hold DGX as of Q2 2020.

Friess Associates reported no remaining Quest Diagnostics position as of Q2 2020 after selling out during the quarter.
Friess Associates sold 49,200 Quest Diagnostics shares in Q2 2020, an estimated $3.95M.
Friess Associates first reported a position in Quest Diagnostics in Q1 2020 and held it in 1 quarter.
Friess Associates's Quest Diagnostics position peaked at $3.95M in Q1 2020.
748 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2020.

Based on Friess Associates's 13F filing for Q2 2020, filed 14 Aug 2020.